The Expression of SIRT1 and DBC1 in Laryngeal and Hypopharyngeal Carcinomas

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Yu, Xue Min ^a   Liu, Ying ^a   Jin, Tong ^a   Liu, Jun ^a,b   Wang, Juan ^a   Ma, Chao ^a   Pan, Xin Liang ^a  

^a SHANDONG UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN DBC1; PROTEIN P53; SIRTUIN 1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; DBC1 PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; HYPOPHARYNX CARCINOMA; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCOSA; PATHOPHYSIOLOGY; PROTEIN DEFECT; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TUMOR DIFFERENTIATION; AGED; GENETICS; HYPOPHARYNX TUMOR; LARYNX TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

AGED; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; HYPOPHARYNGEAL NEOPLASMS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; SIRTUIN 1; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS;

EID: 84879268616     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066975     Document Type: Article

References (36)

1. Wittekindt C, Wagner S, Mayer CS, Klussmann JP (2012) Basics of tumor development and importance of human papilloma virus (HPV) for head and neck cancer. GMS Curr Top Otorhinolaryngol Head Neck Surg.
2. Mao Y, Zhang DW, Lin H, Xiong L, Liu Y, et al. (2012) Alpha B-crystallin is a new prognostic marker for laryngeal squamous cell carcinoma. J Exp Clin Cancer Res 31.
3. Hall SF, Groome PA, Irish J, O'Sullivan B, (2008) The natural history of patients with squamous cell carcinoma of the hypopharynx. Laryngoscope 118: 1362-1371.
4. Boyle P, Ferlay J, (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16: 481-488.
5. Voelter-Mahlknecht S, Mahlknecht U, (2006) Cloning, chromosomal characterization and mapping of the NAD-dependent histone deacetylases gene sirtuin 1. Int J Mol Med 17: 59-67.
6. Imai S, Armstrong CM, Kaeberlein M, Guarente L, (2000) Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403: 795-800.
7. Michan S, Sinclair D, (2007) Sirtuins in mammals: insights into their biological function. Biochem J 404: 1-13.
8. Chen B, Nelson DM, Sadovsky Y, (2006) N-myc down-regulated gene 1 modulates the response of term human trophoblasts to hypoxic injury. J Biol Chem 281: 2764-2772.
9. Chen J, Zhou Y, Mueller-Steiner S, Chen LF, Kwon H, et al. (2005) SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem 280: 40364-40374.
10. Sung JY, Kim R, Kim JE, Lee J, (2011) Balance between SIRT1 and DBC1 expression is lost in breast cancer. Cancer Sci 101: 1738-1744.
11. Jang KY, Kim KS, Hwang SH, Kwon KS, Kim KR, et al. (2009) Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology 41: 366-371.
12. Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, et al. (2007) SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 67: 6612-6618.
13. Cha EJ, Noh SJ, Kwon KS, Kim CY, Park BH, et al. (2009) Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res 15: 4453-4459.
14. Kabra N, Li Z, Chen L, Li B, Zhang X, et al. (2009) SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem 284.
15. Jang KY, Hwang SH, Kwon KS, Kim KR, Choi HN, et al. (2008) SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol 32: 1523-1531.
16. Bradbury CA, Khanim FL, Hayden R, Bunce CM, White DA, et al. (2005) Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 19: 1751-1759.
17. Hida Y, Kubo Y, Murao K, Arase S (2007) Strong expression of a longevity-related protein, SIRT1, in bowen's disease. Arch Dermatol Res. p. 103-106.
18. Wang RH, Sengupta K, Li C, Kim HS, Cao L, et al. (2008) Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 14: 312-323.
19. Kwon HS, Ott M, (2008) The ups and downs of SIRT1. Trends Biochem Sci 33: 517-525.
20. Kim JE, Chen J, Lou Z, (2008) DBC1 is a negative regulator of SIRT1. Nature 451: 583-586.
21. Zhao W, Kruse JP, Tang Y, Jung SY, Qin J, et al. (2008) Negative regulation of the deacetylase SIRT1 by DBC1. Nature 451.
22. Zhang Y, Gu Y, Sha S, Kong X, Zhu H, et al. (2013) DBC1 is over-expressed and associated with poor prognosis in colorectal cancer. Int J Clin Oncol.
23. Trauernicht AM, Kim SJ, Kim NH, Boyer TG, (2007) Modulation of estrogen receptor alpha protein level and survival function by DBC-1. Mol Endocrinol 21: 1526-1536.
24. Kojima K, Ohhashi R, Fujita Y, Hamada N, Akao Y, et al. (2008) A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem Biophys Res Commun 373: 423-428.
25. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
26. Harvey JM, Clark GM, Osborne CK, Allred DC, (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474-1481.
27. Hiraike H, Wada-Hiraike O, Nakagawa S, Saji S, Maeda D, et al. (2011) Expression of DBC1 is associated with nuclear grade and HER2 expression in breast cancer. Exp Ther Med 2: 1105-1109.
28. Ferlay J, Parkin DM, Steliarova-Foucher E, (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46: 765-781.
29. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
30. Srinivas PR, Kramer BS, Srivastava S, (2001) Trends in biomarker research for cancer detection. Lancet Oncol 2: 698-704.
31. Jain KK, (2007) Cancer biomarkers: current issues and future directions. Curr Opin Mol Ther 9: 563-571.
32. Noguchi A, Li X, Kubota A, Kikuchi K, Kameda Y, et al. (2013) SIRT1 expression is associated with good prognosis for head and neck squamous cell carcinoma patients. Oral Surg Oral Med Oral Pathol Oral Radiol 115: 385-392.
33. Byles V, Chmilewski LK, Wang J, Zhu L, Forman LW, et al. (2010) Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K/IGF-1R signaling in human cancer cells. Int J Biol Sci 6: 599-612.
34. Jin Q, Yan T, Ge X, Sun C, Shi X, et al. (2007) Cytoplasm-localized SIRT1 enhances apoptosis. J Cell Physiol 213: 88-97.
35. Gu L, Zhu N, Zhang H, Durden DL, Feng Y, et al. (2009) Regulation of XIAP translation and induction by MDM2 following irradiation. Cancer Cell 15: 363-375.
36. Cohen HY, Lavu S, Bitterman KJ, Hekking B, Imahiyerobo TA, et al. (2004) Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell 13: 627-638.